West Pharmaceutical
379 hedge funds and large institutions have $7.51B invested in West Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 142 increasing their positions, 96 reducing their positions, and 40 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
63% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 40
48% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 96
10% more capital invested
Capital invested by funds: $6.83B → $7.51B (+$685M)
7% more funds holding
Funds holding: 355 → 379 (+24)
1.56% less ownership
Funds ownership: 94.03% → 92.47% (-1.6%)
89% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $26.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$55.6M |
| 2 |
Renaissance Technologies
New York
|
+$29.2M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$23.1M |
| 4 |
Millennium Management
New York
|
+$20.8M |
| 5 |
BlackRock
New York
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$86.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$73.5M |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$56.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$49M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$29M |
WST Hedge Fund Activity: Q1 2019 in Review
379 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2019, worth a combined $7.51B — up 10% from $6.83B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new WST positions and 40 closed out — a net gain of 25 holders — while 142 added to existing stakes and 96 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $55.6M. The largest seller was 1832 Asset Management, exiting entirely with an estimated $86.1M sold.
- 379 institutional investors held West Pharmaceutical (WST) as of Q1 2019, up from 355 in Q4 2018.
- Funds reported $7.51B of West Pharmaceutical stock for Q1 2019, up 10% quarter-over-quarter.
- 65 funds opened new West Pharmaceutical positions in Q1 2019 and 40 closed out, a net change of +25 holders.
- The largest West Pharmaceutical buyer in Q1 2019 was Capital Research Global Investors, an estimated $55.6M added.
- The largest West Pharmaceutical seller in Q1 2019 was 1832 Asset Management, an estimated $86.1M sold.
Based on aggregated 13F filings for Q1 2019.